We investigated the efficacy of nilvadipine, a calcium channel inhibitor, for psychiatric symptoms and tardive dyskinesia in 30 patients with chronic schizophrenia in a placebo-controlled double-blind crossover study. The total scores of the Brief Psychiatric Rating Scale decreased significantly when the patients were on nilvadipine compared with placebo. Improvement was particularly significant in emotional withdrawal and uncooperativeness. Nilvadipine was not effective, however, for tardive dyskinesia. No adverse effects, such as hypotension, occurred. (J Clin Psychopharmacol 1996;16:437-439).
(Yamada, Ashikari, Ohnishi, Yagi, Asai) Department of Neuropsychiatry, School of Medicine, Keio University, Tokyo, Japan; (Yamada, Ashikari) Department of Neuropsychiatry, Jiundou-Naika Hospital, Tokyo, Japan; and (Kanba) Department of Neuropsychiatry, Yamanashi Medical University, Yamanashi, Japan.
Received November 14, 1995; accepted after revision April 12, 1996.
Address requests for reprints to: Shigenobu Kanba, MD, Department of Neuropsychiatry, Yamanashi Medical University, 1110 Shimokato, Tamaho-cho, Nakakoma-gun, Yamanashi, 409-38, Japan.